| Literature DB >> 30181370 |
Marie Gladys Robert1,2, Francis Foguim Tsombeng1,2, Mathieu Gendrot1,2, Joel Mosnier1,2,3, Rémy Amalvict1,2,3, Nicolas Benoit1,2,3, Marylin Torrentino-Madamet1,2,3, Bruno Pradines4,2,3.
Abstract
Resistance to piperaquine has been associated with the amplification of the plasmepsin II gene in Cambodia. None of the 175 African isolates that we analyzed had plasmepsin II gene amplification (piperaquine 50% inhibitory concentration ranged from 0.94 to 137.5 nM), suggesting there is a low prevalence of piperaquine reduced susceptibility in Africa. Additionally, the few isolates with reduced susceptibility to piperaquine did not harbor amplification of the plasmepsin II gene.Entities:
Keywords: Plasmodium falciparum; antimalarial drug; in vitro; malaria; molecular marker; piperaquine; plasmepsin II gene; resistance
Mesh:
Substances:
Year: 2018 PMID: 30181370 PMCID: PMC6201094 DOI: 10.1128/AAC.00374-18
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191